Skip to main content
Galapagos NV logo

Galapagos NV — Investor Relations & Filings

Ticker · GLPG ISIN · BE0003818359 LEI · 549300QKJ78IY0IOV655 BR Manufacturing
Open in API
Filings indexed 2,865 across all filing types
Latest filing 2017-05-16 Regulatory Filings
Country BE Belgium
Listing BR GLPG

About Galapagos NV

https://www.glpg.com/

Galapagos NV is a biotechnology company focused on transforming patient outcomes through scientific innovation. The company is strategically concentrating its efforts on its cell therapy platform, which is engineered for the scalable, decentralized, and rapid production of next-generation treatments. A key feature of this platform is a median 7-day vein-to-vein delivery time. In parallel with this focus, Galapagos is actively seeking partners to take over its portfolio of small molecule assets, including its TYK2 inhibitor program for autoimmune indications. This strategic shift allows the company to prioritize the growth and development of its cell therapy pipeline through internal discovery, partnerships, and acquisitions.

Recent filings

Filing Released Lang Actions
Seven abstracts on filgotinib accepted by EULAR 2017
Regulatory Filings Classification · 95% confidence The document is a press release ("Persbericht") from Galapagos NV dated May 15, 2017, announcing that seven abstracts related to their drug filgotinib have been accepted for presentation at the EULAR 2017 congress. This is an announcement about scientific data being presented at a conference, not the full financial report (10-K), an interim report (IR), or a formal earnings release (ER). It is a general corporate communication regarding scientific progress and conference participation. Since it doesn't fit the specific categories like AGM-R, ER, IR, or CT, and it is a formal announcement, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous corporate update, although 'Investor Presentation' (IP) might be considered if it were the presentation itself. Given the context of an abstract acceptance announcement, RNS is the most appropriate fallback for a non-standard, non-financial regulatory/corporate update.
2017-05-16 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used to furnish reports or other documents that foreign private issuers must make public under home country laws or exchange rules. The text mentions that the Form 6-K includes a press release as Exhibit 99.1 dated May 15, 2017. The document is relatively short (2561 characters) and primarily serves to submit the press release and incorporate it by reference into registration statements. There is no substantive financial data or detailed report content here, only a regulatory filing to provide information to the SEC and public. According to the rules, such filings that do not contain full reports but provide regulatory updates or press releases fall under Regulatory Filings (RNS).
2017-05-16 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. It references a press release attached as Exhibit 99.1 dated May 7, 2017. The text is short (2558 characters) and primarily serves as a cover report to submit the press release. There is no substantive financial data or detailed report content within this document itself. According to the rules, such a document that mainly announces or attaches another report or press release, without containing the report itself, should be classified as a Regulatory Filing (RNS).
2017-05-08 English
6-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, Galapagos NV. Form 6-K is used by foreign private issuers to furnish reports or documents that are required to be made public under the laws of their home country or exchange rules. The document includes a press release as an exhibit and is relatively short (2610 characters). It does not contain detailed financial statements or substantive financial data. The text indicates it is a report submission rather than the report itself. According to the rules, such filings are classified as Regulatory Filings (RNS) because they do not fit into other specific categories and are not full financial reports or announcements of voting results, management changes, or other specific events.
2017-05-02 English
Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
Earnings Release Classification · 95% confidence The document is a press release from Galapagos NV, dated April 29, 2017, announcing the presentation of preclinical data for their drug candidate GLPG1972 at the OARSI annual meeting. The text details scientific findings, partnership information (with Servier), upcoming clinical trial plans (Phase 1b), and includes standard sections like 'About Galapagos' and 'Forward-Looking Statements'. This format—a formal announcement of scientific/business progress, often coinciding with a conference presentation or data readout—is characteristic of an Earnings Release (ER) or a general press release detailing operational updates. Since it is not a full annual report (10-K), a quarterly report (IR), a transcript (CT), or a specific regulatory filing like a Director's Dealing (DIRS) or Proxy Statement (PSI), it best fits the 'Earnings Release' category, as these releases often contain key operational and scientific highlights intended for investors, even if not strictly tied to quarterly financial results. Given the focus on data presentation and pipeline progress, ER is the most appropriate fit among the provided options for a major corporate announcement of this nature. Q2 2017
2017-05-01 English
Galapagos presents pre-clinical data with selective ADAMTS-5 inhibitor GLPG1972 for osteoarthritis at OARSI
Regulatory Filings Classification · 95% confidence The document is a press release dated April 29, 2017, announcing the presentation of pre-clinical data for a drug candidate (GLPG1972) at a scientific conference (OARSI). It details scientific findings, collaboration terms (with Servier), future clinical plans (Phase 1b study initiation), and includes standard 'About' and 'Forward-looking statements' sections typical of corporate news releases. This content is not a formal regulatory filing like a 10-K, an official earnings release (ER), or a comprehensive Interim Report (IR). It is an announcement related to ongoing research and development activities, often shared with investors and the public. Since it is a specific announcement about scientific progress and not a general regulatory filing (RNS), the most appropriate category is Investor Presentation (IP), as these press releases often accompany or summarize data that would be presented to investors, even if the primary event is a scientific meeting. However, given the focus is on presenting data and providing updates on pipeline progress, it aligns closely with the spirit of an Investor Presentation (IP) or a general corporate update. Since it is a news release announcing data presentation, and not the presentation slides themselves, and it is not a formal earnings or financial report, 'Investor Presentation' (IP) is the best fit for detailed pipeline updates disseminated to investors. If 'IP' is strictly for slide decks, then 'RNS' (Regulatory Filings/General Announcement) would be the fallback. Given the detailed nature of the scientific update intended for investors, IP is chosen over the generic RNS.
2017-05-01 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.